Home | Publications | Regulation & Policy | Pricing & Reimbursement place holder
place holder place holder

Pricing & Reimbursement

Managed Markets

Pharmaceutical Reimbursement Strategy, Organizational Structure and Medicare Part D

Publication Date   February 2006
Publisher   Cutting Edge Information
Product Type   Strategic Report
Pages   179
ISBN Number   not applicable
Product Code   CUT045
Ask a question about this product?

Price £2,220.00

approximately: $4,397 | €2,822

Summary


Benchmark your managed markets department's size and structure against those of top-tier firms, mid-size companies, and small pharmas and biotechs. Identify the structural differences and strategic business drivers that differentiate companies in each of these groups, and learn about the pitfalls that commonly affect managed markets departments at each level. Use product-specific headcounts and budgets to lobby for additional resources, and prepare your company's strategy for incorporating the Medicare Part D prescription drug benefit into structural changes, marketing planning and account management realignments.

Managed Markets 2007: Pharmaceutical Reimbursement Strategy, Organizational Structure and Medicare Part D is a cutting-edge guide for companies of all sizes:

  • Top-tier companies' managed markets organizations use this report to compare their account management forces, marketing resources and support staff against the competition; justify headcounts and budgets; and learn the latest strategies, structures, processes and tactics for winning in the changing Medicare Part D arena. The report analyzes the key business drivers, including pharmacoeconomic data collection, span and level of control over insured lives integrated marketing and account management, and account alignment, that differentiate the top-tier company managed care operating environment from that of smaller firms.
  • Mid-size companies use this report to identify the organizational structures and headcounts they need as they expand along the mid-tier spectrum from small operations to those approaching top-tier status. The report's brand-specific budgets and staffing data help ensure that their resource allocations are right on the mark. Strategic insights help these companies develop a detailed understanding of how Part D will affect their products.
  • Small pharmaceutical and biotechnology companies can derive many benefits from this report in a number of areas. Case studies of other small companies' and mid-size and top-tier companies' managed markets organizations present a roadmap for organizational growth from having a few or even no dedicated resources to establishing a small department of five or 10, to a mid-size organization of 20 or 60 FTEs, to a top-tier group of 100 or more managed markets staff. Analysis of key business drivers at the various levels help small companies identify the important clinical, health economics and managed care activities they need to focus on as they grow.

Content


  • The following Is A List of Metrics Included in This Report. While This List Is Not Inclusive of All The Data in The Report, IT Summarizes The Main Categories and Types of Data Included in Each Chapter.
  • Chapter 1:
    • Percentage of companies with dedicated managed markets departments (at top-tier firms, mid-level companies and small pharmas and biotechs)
    • Percentage of companies with centralized managed markets departments
    • Functions that oversee managed markets departments
    • Number of FTEs at every level of Company U's managed markets department (including national accounts, regional accounts and marketing structures)
    • Percentage of growth expected in managed markets marketing organizations at top-tier firms in 2006 and 2008 (at the senior management, line management, line worker/analyst and administrative levels)
    • Percentage of growth expected in managed markets sales organizations at top-tier firms in 2006 and 2008 (at the senior management, account management and administrative levels)
    • Number of FTEs at every level of Company V's managed markets department (including sales, marketing, contracts and government affairs)
    • Number of FTEs at every level of Company W's managed markets department (including national accounts, regional accounts, trade relations, contract operations, government affairs and customer service)
    • Percentage of growth expected in managed markets marketing organizations at mid-size companies in 2006 and 2008 (at the senior management, line management, line worker/analyst and administrative levels)
    • Percentage of growth expected in managed markets sales organizations at mid-size companies in 2006 and 2008 (at the senior management, account management and administrative levels)
    • Company P's managed markets department structure
    • Percentage of growth expected in managed markets marketing organizations at small pharma and biotech companies in 2006 and 2008 (at the senior management, line management, line worker/analyst and administrative levels)
    • Percentage of growth expected in managed markets sales organizations at small pharma and biotech companies in 2006 and 2008 (at the senior management, account management and administrative levels)
  • Chapter 2:
    • Medicare Part D tiered structure
    • Number of Medicare beneficiaries with prescription drug coverage
    • Projected annual increases in Medicare Part D annual premiums, deductibles, upper limits for 75% coverage, catastrophic coverage tier levels, and coverage gaps through 2013
  • Chapter 3:
    • Managed markets budgets and staff for 2 products from pre-clinical development, Phase I, Phase II, Phase III, Registration & Launch Stage, Year 1 on Market, Year 2 on Market and Year 3 on Market
    • 5 companies' 2006 managed markets sales budgets (including the total number of therapeutic areas and products they support)
    • 12 companies' 2006 managed markets marketing budgets (including the total number of therapeutic areas and products they support)
    • 2006 average US managed markets marketing budgets by company size (top-tier firms, mid-size companies, and small pharmas and biotechs)
    • 2006 average US managed markets sales budgets by company size (top-tier firms, mid-size companies, and small pharmas and biotechs)
    • 10 companies' 2006 budgets for commercial managed care marketing, federal Medicare/Medicaid marketing, state Medicare/Medicaid marketing, long-term care marketing, and trade relations marketing (in real dollars and by percent of total managed markets marketing spend)
    • 5 companies' 2006 budgets for commercial managed care sales, federal Medicare/Medicaid sales, state Medicare/Medicaid sales, long-term care sales, and trade relations sales (in real dollars and by percent of total managed markets marketing spend)
    • 8 companies' 2006 managed markets marketing and sales budgets for commercial managed care, federal Medicare/Medicaid, state Medicare/Medicaid, long-term care, and trade relations
    • Employee compensation: base salary, bonus and benefits compensation for managed markets marketing and sales senior executives, line managers and line workers at small, medium and large companies